Keywords
How to Cite
Abstract
Analysis of the Efficacy and Safety of Ozempic and Saxenda in the Treatment of Obesity: A Comprehensive Review: The use of innovative therapies to treat obesity, such as Ozempic and Saxenda, represents an advanced approach in managing this endocrine condition that can significantly impact patients' quality of life. These therapies offer significant alternatives to conventional treatments or other available interventions. However, careful selection of the most suitable therapy is crucial, considering the various options available, including different formulations and administration regimens. Each of these options presents its own technical requirements and clinical considerations, highlighting the importance of examining these differences to assist healthcare professionals and patients in making informed decisions.
In exploring the various options of innovative therapies for obesity, it is essential to assess not only efficacy in terms of improving parameters related to obesity but also factors such as safety, tolerability, and impact on quality of life. Additionally, it is essential to evaluate patients' overall outcomes after initiating therapy, taking into account patient adherence, potential side effects, and satisfaction with treatment. This comprehensive evaluation can provide valuable insights into the therapy's impact on daily life and patient well-being.
Another relevant aspect to consider is treatment customization, taking into account individual patient needs and preferences, as well as their specific clinical condition. This may involve a thorough analysis of the patient's medical history, expectations regarding treatment, and lifestyle. By adopting a patient-centered approach, healthcare professionals can ensure that the chosen therapy meets specific needs and provides the best possible outcomes.
In summary, the analysis and understanding of options for innovative therapies for obesity treatment, such as Ozempic and Saxenda, and their evaluation of overall outcomes are crucial to ensuring treatment success and patient satisfaction. By considering a variety of factors, from clinical efficacy to impact on quality of life, healthcare professionals can make more informed and personalized decisions, thereby improving the quality of care and outcomes for patients with this endocrine condition.
References
ALADEL, Alanoud; ALJAOUNI, Jamilah; BASAAD, Reem. Effect of Liraglutide on Fat Mass Percentage Among Overweight and Obese Adults with Type 2 Diabetes: A Systematic Review. Diabetes, Metabolic Syndrome and Obesity, v. 16, p. 3381–3391, 2023.
BARBOZA, Joshuan J. et al. Efficacy of Liraglutide in Non-Diabetic Obese Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J. Clin. Med., v. 11, p. 2998, 2022.
CORNEJO-ESTRADA, Alejandra et al. Efficacy of Liraglutide in Obesity in Children and Adolescents: Systematic Review and Meta-Analysis of Randomized Controlled Trials. Children, v. 10, p. 208, 2023.
DENG, You et al. Effect of semaglutide and liraglutide in individuals with obesity or overweight without diabetes: a systematic review. Ther Adv Chronic Dis, v. 13, p. 1–14, 2022.
GUO, Xiaonan et al. The Antiobesity Effect and Safety of GLP-1 Receptor Agonist in Overweight/Obese Patients Without Diabetes: A Systematic Review and Meta-Analysis. Horm Metab Res, v. 54, p. 458–471, 2022.
RUSEVA, Aleksandrina et al. Semaglutide 2.4 mg clinical outcomes in patients with obesity or overweight in a real-world setting: A 6-month retrospective study in the United States (SCOPE). Obes Sci Pract, p. e737, 2024.
Shinje et al. Efficacy and Safety of the New Appetite Suppressant, Liraglutide: A Meta-Analysis of Randomized Controlled Trials. Endocrinol Metab, v. 36, p. 647-660, 2021.
XIANG, J. et al. Clinical effectiveness of semaglutide on weight loss, body composition, and muscle strength in Chinese adults. European Review for Medical and Pharmacological Sciences, v. 27, p. 9908-9915, 2023.
XIE, Zeyu et al. Efficacy and Safety of Liraglutide and Semaglutide on Weight Loss in People with Obesity or Overweight: A Systematic Review. Clinical Epidemiology, v. 14, p. 1463–1476, 2022.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2024 Davi Ferreira Pires, Marcela Carvalho Marcovechio Fonseca , Luísa Ledoux Cabanelas , Rodrigo Carvalho Marcovechio Fonseca , Maria Julia Magalhães Lobo